GSK stock has delivered a roughly 54.5% total return over the past 5 years, yet recent weakness and a high value score suggest the market may still be pricing the pharmaceutical group cautiously. Investors now have to reconcile a solid longer term track record with a share price that screens as cheap on broader valuation checks.
- Around 54.5% total return over 5 years points to meaningful long run value creation for holders who stayed invested.
- Progress on cancer therapies and an mRNA flu vaccine candidate can support expectations for future cash flows, while clinical and regulatory risks may still weigh on how much investors are willing to pay today.
- A high value score, where GSK screens attractively on 5 of 6 checks, indicates the broader checks lean cheap for this stock.
The issue now is whether GSK’s current share price already reflects these strengths and risks or still leaves room for further upside in the valuation.
Compare GSK’s setup with other high quality shares that also screen as attractively priced using the 10 high quality undervalued stocks.
Does GSK Look Undervalued on Earnings?
The P/E ratio fits GSK well because earnings quality is central to how investors typically judge large pharmaceutical groups. On this metric, GSK trades on about 14.8x earnings, which is well below the broader pharmaceuticals industry average of roughly 22.0x and far under the peer average near 46.0x.
A tailored fair P/E multiple for GSK of about 34.9x, based on factors such as its margins, risk profile and sector, sits much higher than where the stock currently trades. Even with recent interest around its mRNA flu vaccine program and oncology partnerships, the present P/E leaves a wide gap to that fair ratio. This suggests that the market is placing a relatively low price on the existing earnings stream.
On this earnings multiple, GSK stock appears undervalued relative to both sector norms and the fair P/E suggested by its fundamentals.
See what the numbers say about this price — find out in our valuation breakdown.
The GSK Narrative: What Would Justify Today's Price?
GSK’s valuation puzzle raises a simple question for you as a shareholder or potential buyer. Narratives on Simply Wall St’s Community page spell out which future paths for GSK’s growth, margins and earnings would line up with a much higher or lower price than today. Each one sets out the assumptions behind its fair value in a clear way, so you can compare those expectations with the actual results as they come through.
Community views on GSK sit far apart, with one camp focused on pipeline reinvestment and another fixated on pricing, patents and legal risk.
Bull case: 18% undervalued
"Strong volume growth in key high-margin areas like oncology (Jemperli, Blenrep), immunology (Benlysta, Nucala, depemokimab), and HIV (long-acting injectables) demonstrates GSK's ability to capture premium pricing and leverage long-term trends toward therapies, positively impacting future earnings and supporting margin expansion as these portfolios scale."
Read the full Bull Case to see why GSK could be undervalued
Bear case: 22% overvalued
"The company is approaching several major patent cliffs, most notably in the HIV portfolio, which will trigger a rapid decline in high-margin product sales as generics and biosimilars erode exclusivity, leading to steep reductions in both revenue and net margins from 2028 onward."
Read the full Bear Case to see why GSK could be overvalued
Do you think there's more to the story for GSK? Head over to our Community to see what others are saying!
The Bottom Line
GSK screens as undervalued on earnings, with the current P/E sitting well below both industry norms and the tailored fair multiple implied by its profile. That discount only pays off if the business can sustain the earnings power that the bull case expects in oncology, immunology and HIV while managing the patent and legal risks that worry sceptics. The key question from here is whether today’s lower multiple reflects an overly cautious mood or a justified buffer against those pipeline and patent uncertainties.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com